Multi-Functional Cell Therapies Summit 2021
May 4-6, 2021 – Virtual
ARTEMIS Technology with Enhanced T-Cell Infiltration in Solid Tumors
May 4-6, 2021 – Virtual
ARTEMIS Technology with Enhanced T-Cell Infiltration in Solid Tumors
April 9, 2021 – Virtual
ARTEMIS Antibody Redirected TCR T-Cell Therapies for the Treatment of Solid Tumors
March 16-18, 2021 – Virtual
Developing T-Cell Immunotherapy for Solid Tumors
January 29, 2021 – Virtual
Developing T-Cell Immunotherapy for Solid Tumors
December 1-3, 2020 – Virtual
Live Panel: Where are we going? CAR-T & TCR therapy development beyond 2020
October 26- 28, 2020 – Virtual Summit
ARTEMIS Antibody TCR T-Cell Therapy for Solid Tumors
October 19 – 22, 2020 – Virtual Conference
Optimizing Viral Vector Production
September 8- 11, 2020 – Webinar
ARTEMIS Antibody TCR T-Cell Therapy for Solid Tumors
June 29 – July 2, 2020 – Webinar
ARTEMIS Antibody TCR T-Cell Therapy for Solid Tumors
March 1-4, 2020 – Boston Marriott Copley Place, Boston, MA
ARTEMIS Antibody Redirected TCR Therapies for Solid Tumors
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.